DROMOSTANOLONE PROPIONATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H36O3
Molecular Weight	360.5301
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)[C@H](C)C[C@]34C

InChI

InChIKey=NOTIQUSPUUHHEH-UXOVVSIBSA-N

InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://steroid.es/drostanolone.html

Dromostanolone Propionate (known by the brand names Masteron and Drolban) was invented by Syntex in 1959. About 10 years later it was released on the American market by Lilly as brand name Drolban. The drug was first approved in the USA for use as a treatment of female breast cancer. However, the profile of side-effects included pronouncement of male characteristics in women and when more effective breast cancer treatments came to market drostanolone was gradually phased out. No longer used clinically dromostanolone propionate became very popular in the bodybuilding community. Today dromostanolone propionate remains on the list of approved medications, but it is not being manufactured or sold by pharmaceutical companies. It is still produced illegally by underground labs for use in the bodybuilding community.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3758193	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Female breast cancer 2 Sources: http://steroid.es/drostanolone.html	Primary		Approved 8429	Drolban Approved Use Unknown

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 day REVIEW https://books.google.ru/books?id=afKLA-6wW0oC&pg=PT517&redir_esc=y#v=onepage&q&f=false	single, intramuscular		DROMOSTANOLONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 4 times / day multiple, oral Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4606631	unhealthy, adult n = 9 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/4606631	Disc. AE: Hypertriglyceridemia... AEs leading to discontinuation/dose reduction: Hypertriglyceridemia (5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/4606631

AEs

AE	Significance	Dose	Population
Hypertriglyceridemia	5 patients Disc. AE	100 mg 4 times / day multiple, oral Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4606631	unhealthy, adult n = 9 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/4606631

Sourcing

Vendor/Aggregator	ID	URL
AAA Chemistry	AR-1D8078
ABI Chem	AC1L1LLU
ABI Chem	AC1Q6OL6
AHH Chemical co.,ltd	MT-50739	http://www.ahhchemical.com/product/MT-50739.html
AN PharmaTech	AN-41745
Ambinter	Amb17613605	http://www.ambinter.com/reference/17613605
ChemMol	49425900	http://www.chemmol.com/chemmol/49425900.html
ChemMol	99111259	http://www.chemmol.com/chemmol/99111259.html
ChemShuttle	TQP0581	https://www.chemshuttle.com/catalogsearch/result/?q=58-19-5&cat=
Chemieliva Pharmaceutical Co., Ltd	PBCM0656318
Compound Cloud	6011
MuseChem	R066915	https://www.musechem.com/product/R066915.html
NCI Plated 2007	26198
NovoSeek	6011
OChem	8266	http://www.ocheminc.com/index.php?act=psearch&pid=198D322
PI Chemicals	PI-21734
Scientific Exchange	F-124886
Smolecule	S526640	http://www.smolecule.com/products/s526640
THE BioTek	bt-266543	https://www.thebiotek.com/product/inhibitors/bt-266543
Tetrahedron	TS60442
Toronto Research Chemicals	KIT1085
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	PH-1081RA
ZINC	ZINC000003875387	http://zinc15.docking.org/substances/ZINC000003875387

PubMed

Title	Date	PubMed
Endocrinological and pathological effects of anabolic-androgenic steroid in male rats.	2004 Aug	15351799
Myocardial infarction with intracoronary thrombus induced by anabolic steroids.	2004 Dec	15590370
Intracerebroventricular self-administration of commonly abused anabolic-androgenic steroids in male hamsters (Mesocricetus auratus): nandrolone, drostanolone, oxymetholone, and stanozolol.	2005 Jun	15998196
6alpha-Methylandrostenedione: gas chromatographic mass spectrometric detection in doping control.	2008	18181236
Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.	2008 Mar 28	18373855
Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes.	2009 Mar	19056412

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Name

Type

Language

DROMOSTANOLONE PROPIONATE

Official Name

English

DROMOSTANOLONE PROPIONATE [ORANGE BOOK]

Common Name

English

NSC-1298

Code

English

17β-Hydroxy-2α-methyl-5α-androstan-3-one propionate

Common Name

English

DROSTANOLONE PROPIONATE [JAN]

Common Name

English

32379

Code

English

DROSTANOLONE PROPIONATE

Common Name

English

NSC-12198

Code

English

DROLBAN

Brand Name

English

DROMOSTANOLONE PROPIONATE [USAN]

Common Name

English

MASTERON

Brand Name

English

PERMASTRIL

Brand Name

English

ANDROSTAN-3-ONE, 2-METHYL-17-(1-OXOPROPOXY)-, (2.ALPHA.,5.ALPHA.,17.BETA

Common Name

English

MASTERID

Brand Name

English

DROSTANOLONE PROPIONATE [MART.]

Common Name

English

DROMOSTANOLONE PROPIONATE [MI]

Common Name

English

Drostanolone propionate [WHO-DD]

Common Name

English

Classification Tree Code System Code

DEA NO.

4000